DnB Asset Management AS Acquires 15,256 Shares of Boston Scientific Corporation $BSX

Key Points

• DnB Asset Management AS increased its holdings in Boston Scientific Corporation by 3.3% during the first quarter, acquiring an additional 15,256 shares, bringing their total to 475,528 shares valued at approximately $47.97 million.
• Insider trading activity included the sale of 17,313 shares by EVP Arthur C. Butcher and 4,000 shares by Director Edward J. Ludwig, with both transactions resulting in significant decreases in their respective holdings.
• Boston Scientific recently reported better-than-expected financial results, with revenues of $5.06 billion for the quarter, surpassing analyst expectations of $4.89 billion, and setting a Q3 2025 earnings guidance of $0.700-0.720 EPS.

DnB Asset Management AS raised its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 3.3% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 475,528 shares of the medical equipment provider's stock after buying an additional 15,256 shares during the quarter. DnB Asset Management AS's holdings in Boston Scientific were worth $47,971,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. Brighton Jones LLC grew its holdings in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares during the last quarter. Bank Pictet & Cie Europe AG grew its holdings in Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after buying an additional 21,173 shares during the last quarter. Highview Capital Management LLC DE grew its holdings in Boston Scientific by 6.2% in the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock valued at $2,189,000 after buying an additional 1,439 shares during the last quarter. Aptus Capital Advisors LLC grew its holdings in Boston Scientific by 17.3% in the 4th quarter. Aptus Capital Advisors LLC now owns 11,692 shares of the medical equipment provider's stock valued at $1,044,000 after buying an additional 1,723 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in Boston Scientific in the 4th quarter valued at approximately $297,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded up $0.92 during midday trading on Monday, hitting $108.14. 7,454,396 shares of the company were exchanged, compared to its average volume of 7,464,520. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm has a market cap of $160.23 billion, a P/E ratio of 64.37, a PEG ratio of 2.58 and a beta of 0.65. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $108.94. The firm has a 50 day simple moving average of $104.77 and a 200-day simple moving average of $102.15.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific's revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $18,397,457 over the last 90 days. Corporate insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Truist Financial raised their target price on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a report on Thursday, July 24th. UBS Group raised their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Robert W. Baird raised their price objective on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Leerink Partners started coverage on Boston Scientific in a research report on Monday, June 16th. They issued an "outperform" rating and a $118.00 price objective for the company. Finally, Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average target price of $117.79.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.